摘要
目的 探讨芪甲利肺胶囊辅助治疗复治肺结核的疗效及安全性.方法 收集2010年6月至2012年6月新乡医学院第一附属医院结核内科住院的200例复治肺结核患者,以数字表法随机按1：1分为观察组100例和对照组100例,所有患者均采用2 HRZES/6 HRE方案抗结核治疗,观察组在此基础上加用芪甲利肺胶囊.观察组和对照组分别有97例和98例完成治疗,比较两组的痰菌阴转率、病灶显效率、空洞闭合率、细胞免疫功能改善等方面的差异.采用SPSS 13.0统计软件,计量资料采用t检验,计数资料采用x^2检验,P＜0.05为差异有统计学意义.结果 强化期结束和疗程结束时观察组75例菌阳患者的痰菌阴转率分别为81.33％（61/75）和94.67％（71/75）;对照组74例菌阳患者的痰菌阴转率分别为67.57％（50/74）和83.78％（62/74）,两组不同时期比较差异均有统计学意义（x^2值分别为4.36和6.01,P值均＜0.05）.强化期治疗结束时观察组的病灶显效率及空洞闭合率分别为74.23％（72/97）和26.80％（26/97）,高于对照组的54.08％（53/98）和12.％（12/98）（x^2值分别为3.91和6.59,P值均＜0.05）.疗程结束时观察组的病灶显效率及空洞闭合率分别为93.82％（91/97）和55.67％（54/97）,高于对照组的78.57％（77/98）和30.61％（30/98）（x^2值分别为9.49和12.48,P值均＜0.05）.治疗结束后观察组的免疫功能检测CD3＋、CD4＋、CD4＋/CD8＋均值分别为（67.13±6.98）％、（44.22±8.11）％和1.61±0.33,明显高于对照组的（62.03±6.12）％、（41.15±7.26）％和1.50±0.34,差异有统计学意义（t值分别为5.42、2.78和2.29,P值均＜0.05）.结论 芪甲利肺胶囊辅助治疗复治肺结核能提高痰菌阴转率、病灶显效率及空洞闭合率,加快临床症状的消失,提高患者的细胞免疫功能.
Objective To evaluate the efficacy and safety of Qijialifei capsule,a kind of Chinese traditional medicine,as adjuvant treatment for retreatment pulmonary tuberculosis.Methods Two hundred cases of retreatment pulmonary tuberculosis hospitalized in the First Affiliated Hospital of Xinxiang Medical College from June 2010to June 2012 were randomly divided into the observation group （100 cases） and the control group （100 cases）.The base condition of two groups was comparability.All patients received the therapy of 2HRZES/6HRE.The patients in the observation group took Qijialifei capsule.Ninety seven cases in the observation group and 98 cases in the control group completed the treatment.Then comparisons were made between the two groups in the sputum tubercle bacillus conversion rate,focus improvement rate,cavity dosing rate,the cellular immune function,and improvement of clinical symptoms.The software SPSS 13.0 was used,measurement data and enumeration data were compared with t test and x^2 test,respectively,P〈0.05 was considered statistically significant.Results At the end of intensified therapy period and the end of the whole therapy,the sputum tubercle bacillus conversion rate in the observation group （81.33% （61/75）,94.67%（71/75）） was significantly higher than those in the control group （67.57%（50/74）,83.78% （62/74））,there were significant differences between the two groups（x^2 4.36,6.01,all P〈0.05）.At the end of intensified therapy period,the focus improvement rate and the cavity dosing rate in the observation group （74.23% （72/97）,26.80% （26/97）） were higher than those in the control group （54.08%（53/98）,12.24%（12/98）） （x^2 3.91,6.59,all P〈0.05）.At the end of the whole therapy the focus improvement rate and the cavity dosing rate in the observation group （93.82 % （91/97）,5 5.67 % （5 4/97）） were higher than those in the control group （78.57 %0 （77/98）,30.61% （30/98） （x^2-9.49,12.48,P〈0.05）.By the end of the whole therapy,the numbers of CD3＋ 、CD4＋ 、CD4＋/CD8＋ of patients in the observation group （（67.13± 6.98）%,（44.22±8.11） %,1.61±0.33） was higher than those in the control group （（62.03±6.12） %,（41.15±7.26） %,1.50± 0.34）,with significant differences between the two group （t 5.42,2.78,2.29,all P〈0.05）.Conclusion Qijialifei capsule as adjuvant treatment can improve the sputum tubercle bacillus conversion rate,radiographic focus improvement rate,and cavity closing rate in the treatment for patients with retreatment pulmonary tuberculosis,which also improves the cellular immune function of patients and alleviate the symptoms.
出处
《中国防痨杂志》
CAS
2014年第11期948-952,共5页
Chinese Journal of Antituberculosis
关键词
结核
肺/中药疗法
中成药
Tuberculosis, pulmonary/traditional Chinese medicine therapy
Chinese patent drugs
